The misinformed bears who are calling for massive dilution haven't done DD on NDRA. They are "assuming" NDRA will use the standard, pre-revenue biotech gameplan.
Most don't even know about partners Starfish Medical and CriTech Research in creating the hardware/software solutions & that Starfish will also manufacture TAEUS. NDRA is using the "asset light model" to perfection & will extend it beyond the development stage into the commercialization phase.
FM from last CC: "As part of our capital efficient operating model, we continue to leverage high quality & flexible service providers such as our development partner, StarFish Medical, rather than burdening our business with facility and staff overhead. This allows us to wind down our engineering spending & shift our resources towards commercialization without appreciably increasing our burn."
"Our goal and what I’ve seen and experienced that works well is build out a small team of ENDRA specialists in the key markets that support both the partner sales reps, GE in this case, support the customers during the demonstration and sale and then afterwards. And we find it helps amplify our sales channel abilities without burdening ourselves with a massive overhead. So, our plan is really to have about five ENDRA specialists in Europe, about five in the U.S. and build that commercial adoption from there."
In other words, leaning on GE is part of the "asset light model" strategy...very obvious NDRA is set up for a future GE buyout. Once TAEUS data is released the ball will be in GE's court, I don't expect them to wait very long.
NDRA operating expenses Q2, including contract development vendors, were $2.3M. Where's the need for massive dilution?
